Novartis’s big wager on RNAi approaches the finish line

Novartis’s big wager on RNAi approaches the finish line

Source: 
EP Vantage
snippet: 

The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.